Boceprevir/peginterferon-α-2b/ribavirin
1
Reactions 1472, p10-11 - 5 Oct 2013 S Boceprevir/peginterferon-α-2b/ribavirin Fatigue, anaemia, and syncope: case report A man [age at reaction onset not clearly stated] developed fatigue, anaemia, and syncope during treatment with boceprevir, peginterferon-α-2b, and ribavirin [routes and durations of treatments to reactions onsets not stated; not all dosages stated]. The man, who had been diagnosed with hepatitis C virus (HCV) in 1995, was initially treated with traditional interferon in 1996. In 1998, he was treated with interferon and ribavirin and in 2002 he was treated with peginterferon-α-2b and ribavirin. He developed progressive liver disease and underwent a liver transplant in April 2007. Post-transplant, he had recurrent HCV infection and he developed chronic active hepatitis and bridging fibrosis. In started treatment in June 2009 with peginterferon-α-2b and ribavirin. He relapsed after 48 weeks of therapy. In January 2011, a biopsy showed cirrhosis. He received a triple therapy regimen consisting of a 4-week lead-in phase with peginterferon-α-2b and ribavirin 800mg. Boceprevir was then added. After 32 weeks of triple therapy, boceprevir was stopped and therapy continued for 12 weeks with peginterferon-α-2b and ribavirin. He developed fatigue, anaemia, and syncope, which required hospitalisation. The man’s anaemia was managed by reducing the dosage of ribavirin to 600mg and later to 200mg. He also received an erythropoietin-stimulating agent and blood transfusion. He completed 48 weeks of therapy successfully and was HCV RNA negative 12 weeks after stopping therapy [outcomes of ADRs not stated]. Author comment: "Adverse events (AEs) of therapy included fatigue, anemia, and syncope, requiring hospital admission." Reddy KR, et al. Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation. Hepatology 58: 1181-1184, No. 3, Sep 2013. Available from: URL: http://dx.doi.org/10.1002/hep.26612 - USA 803093742 1 Reactions 5 Oct 2013 No. 1472 0114-9954/13/1472-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Transcript of Boceprevir/peginterferon-α-2b/ribavirin
Reactions 1472, p10-11 - 5 Oct 2013
SBoceprevir/peginterferon-α-2b/ribavirin
Fatigue, anaemia, and syncope: case reportA man [age at reaction onset not clearly stated] developed
fatigue, anaemia, and syncope during treatment withboceprevir, peginterferon-α-2b, and ribavirin [routes anddurations of treatments to reactions onsets not stated; not alldosages stated].
The man, who had been diagnosed with hepatitis C virus(HCV) in 1995, was initially treated with traditional interferonin 1996. In 1998, he was treated with interferon and ribavirinand in 2002 he was treated with peginterferon-α-2b andribavirin. He developed progressive liver disease andunderwent a liver transplant in April 2007. Post-transplant, hehad recurrent HCV infection and he developed chronic activehepatitis and bridging fibrosis. In started treatment inJune 2009 with peginterferon-α-2b and ribavirin. He relapsedafter 48 weeks of therapy. In January 2011, a biopsy showedcirrhosis. He received a triple therapy regimen consisting of a4-week lead-in phase with peginterferon-α-2b and ribavirin800mg. Boceprevir was then added. After 32 weeks of tripletherapy, boceprevir was stopped and therapy continued for12 weeks with peginterferon-α-2b and ribavirin. He developedfatigue, anaemia, and syncope, which required hospitalisation.
The man’s anaemia was managed by reducing the dosage ofribavirin to 600mg and later to 200mg. He also received anerythropoietin-stimulating agent and blood transfusion. Hecompleted 48 weeks of therapy successfully and was HCVRNA negative 12 weeks after stopping therapy [outcomes ofADRs not stated].
Author comment: "Adverse events (AEs) of therapyincluded fatigue, anemia, and syncope, requiring hospitaladmission."Reddy KR, et al. Treatment of chronic hepatitis C with protease inhibitor-basedtherapy after liver transplantation. Hepatology 58: 1181-1184, No. 3, Sep 2013.Available from: URL: http://dx.doi.org/10.1002/hep.26612 - USA 803093742
1
Reactions 5 Oct 2013 No. 14720114-9954/13/1472-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
